Novo's Disappointment with Former Pfizer Rival Drug
Novo Nordisk expresses disappointment with a drug it previously contested with Pfizer. Meanwhile, Revolution and Tango show encouraging cancer results, and Incyte acquires a bleeding disorder treatment.
Editorial Staff
1 min read
Updated 1 day ago
Novo Nordisk has reportedly expressed underwhelming results from a drug that it once competed against Pfizer for. This development raises questions about the drug's potential in the market.
In related biotech news, the companies Revolution and Tango have announced promising results in their cancer treatments, indicating progress in the fight against the disease.
Additionally, Incyte has made headlines with its acquisition of a drug aimed at treating bleeding disorders, further expanding its portfolio in the biotech sector.